Results from the GALLIUM trial, which were presented as a Late-Breaking Abstract at the 2016 ASH Annual Meeting, showed that first-line treatment with obinutuzumab led to longer progression-free survival than rituximab.
Results from the GALLIUM trial, which were presented as a Late-Breaking Abstract at the 2016 ASH Annual Meeting, showed that first-line treatment with obinutuzumab led to longer progression-free survival than rituximab.
Connect with us:
CURRENT ISSUE
September 2022
